生物技术公司Organogenesis Holdings Inc（股票代码：ORGO）在盘后交易中遭遇重创，股价大跌20.23%，引发投资者关注。
根据公司最新发布的2025年第一季度财报，Organogenesis的业绩表现远低于市场预期。财报显示，公司第一季度营收为8670万美元，不仅低于分析师预期的9077万美元，更是大幅下滑至1.1亿美元前值。每股收益方面，公司报告-0.10美元的亏损，同样远低于预期的-0.03美元和前值-0.01美元。
这份令人失望的财报无疑是导致Organogenesis股价暴跌的主要原因。营收和盈利能力的双重下滑可能引发投资者对公司未来增长前景的担忧。市场分析人士指出，如此大幅度的业绩下滑可能表明公司面临严峻的经营挑战，投资者可能需要重新评估公司的长期发展战略和市场竞争力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.